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ABSTRACT
Objectives: Designing studies with an internal pilot
phase may optimise the use of pilot work to inform
more efficient randomised controlled trials (RCTs).
Careful selection of preagreed decision or ‘progression’
criteria at the juncture between the internal pilot and
main trial phases provides a valuable opportunity to
evaluate the likely success of the main trial and
optimise its design or, if necessary, to make the
decision not to proceed with the main trial. Guidance
on the appropriate selection and application of
progression criteria is, however, lacking. This paper
outlines the key issues to consider in the optimal
development and review of operational progression
criteria for RCTs with an internal pilot phase.
Design: A structured literature review and exploration
of stakeholders’ opinions at a Medical Research
Council (MRC) Hubs for Trials Methodology Research
workshop. Key stakeholders included triallists,
methodologists, statisticians and funders.
Results: There is considerable variation in the use of
progression criteria for RCTs with an internal pilot
phase, although 3 common issues predominate: trial
recruitment, protocol adherence and outcome data.
Detailed and systematic reporting around the decision-
making process for stopping, amending or proceeding
to a main trial is uncommon, which may hamper
understanding in the research community about the
appropriate and optimal use of RCTs with an internal
pilot phase. 10 top tips for the development, use and
reporting of progression criteria for internal pilot
studies are presented.
Conclusions: Systematic and transparent reporting of
the design, results and evaluation of internal pilot trials
in the literature should be encouraged in order to
facilitate understanding in the research community and
to inform future trials.
INTRODUCTION
Well-designed and conducted randomised
controlled trials (RCTs) that are reported in
full have the potential to change clinical
practice and inﬂuence health policy and
decision-making.1 Many trials, however, face
challenges in design and conduct, for
example, in relation to recruitment, adher-
ence, outcome assessment, sample size and
follow-up. Methods to improve the quality of
trial conduct and the efﬁcient use of
resources by earlier identiﬁcation of studies
that cannot be successfully delivered are,
therefore, important and may include the
use of feasibility and pilot studies.2–6 A
recent publication by Kistin and Silverstein6
has concisely outlined the many potential
uses of pilot work, with emphasis on enhan-
cing the efﬁciency and internal validity of
the subsequent deﬁnitive trial. These include
piloting key study logistics such as recruit-
ment, intervention delivery and adherence
and identifying potential barriers and
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
study to explore and summarise the key issues
to consider when developing and using progres-
sion criteria for randomised controlled trials with
an internal pilot phase, where guidance was pre-
viously lacking.
▪ This study was informed by a structured search
of the trials literature and explored the opinions
of a large number and wide variety of key stake-
holders, including triallists, methodologists, sta-
tisticians and funding bodies.
▪ The work was undertaken in the UK and is illu-
strated with examples from a number of National
Institute for Health Research (NIHR)-funded
studies, which may not represent the full vari-
ability of trials observed in other contexts or
settings.
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facilitators to eventual intervention dissemination and
implementation. While there are no universally accepted
deﬁnitions of the different types of feasibility and pilot
studies,7–12 a new conceptual framework has recently
been proposed by Eldridge and colleagues for deﬁning
pilot and feasibility studies conducted in preparation for
an RCT. This framework describes pilot studies as a
subset of feasibility studies: a feasibility study asks
‘whether something can be done, should we proceed
with it, and if so, how’,13 whereas a pilot study ‘may ask
the same questions but also has a speciﬁc design feature:
in a pilot study, a future study, or part of a future study,
is conducted on a smaller scale’. This deﬁnition of a
pilot study is similar in some ways to the deﬁnition pro-
posed by the UK National Institute for Health Research,
which describes how pilot studies may still have some
feasibility objectives but focus largely on uncertainties
around the processes of the main study; for example, to
ensure that recruitment, randomisation, intervention
and follow-up assessments all run smoothly,12 thereby
allowing the methods used in the main study to be opti-
mised. Using either set of deﬁnitions, two types of pilot
study can be distinguished. An ‘external pilot’ is a
rehearsal of the main study where the outcome data are
not included as part of the main trial outcome data set.
Alternatively, the pilot phase may form the ﬁrst part of
the trial and the outcome data generated may contrib-
ute to the ﬁnal analyses. This is called an ‘internal pilot’
and is intended to offer advantages in terms of preserv-
ing efﬁciency in RCTs, preventing waste of valuable
resources and avoiding recruiting participants to a trial
that may not succeed.
A key milestone in a trial with an internal pilot phase
is the progression from the pilot (ﬁrst) phase to the
main (second) trial phase. This juncture is important
because it provides an opportunity to reﬂect on the via-
bility of the trial by allowing RCT processes to be for-
mally reviewed and decisions to be made about whether
it is appropriate for the study to proceed to the main
trial phase or whether it is necessary or possible to
modify the operational aspects of the design to promote
success. Ideally before the study starts, a trial team
together with the funding body would identify prespeci-
ﬁed ‘progression’ or ‘decision’ criteria that are used to
indicate whether targets have been met during the
internal pilot phase and the main trial should
proceed.12 Rather than progression criteria being con-
sidered on a simple stop/go basis, it may be preferable
to explore whether the trial can proceed with modiﬁca-
tions, similar to a red/amber/green trafﬁc light system:
stop/red (eg, when there are intractable issues that
cannot be remedied), amend/amber (where there are
remediable issues, thereafter proceeding with caution)
or continue/green (where there are no concerning
issues that threaten the success of the trial). These pre-
speciﬁed criteria are set in order to judge the viability of
completing the main trial within the planned timetable
and budget and usually address the key areas of
uncertainty or risk that could inﬂuence the success of
the trial.
Establishing the progression criteria at the outset of
the trial may be considered essential but there is little
published advice about how to do this optimally. To
address this uncertainty, the Medical Research Council
(MRC) Hubs for Trials Methodology Research hosted a
1-day workshop to consider key issues in the develop-
ment and review of progression criteria when the design
of an RCT includes an internal pilot phase.
Workshop methodology
Discussion at this workshop was informed by literature
reviews undertaken by two MRC Hubs for Trials
Methodology Research (ConDuCT-II and the North
West), details of which have been published previously.7
First, PubMed was searched for articles with ‘pilot
studies’ in the title (inception to 03/04/2013) to iden-
tify review and methodology papers published in English
where pilot work was discussed. Of the 289 publications
identiﬁed in the search, full-text articles of 40 papers
were identiﬁed and deﬁnitions of pilot work were
extracted and examined (KNLA, JMB, EOF). All terms
used to describe pilot work and deﬁnitions were
recorded verbatim. The terms identiﬁed in this initial
review informed search strategies for searches of the top
10 impact factor medical journals that endorse
CONSORT guidelines (New England Journal of Medicine;
The Lancet; Journal of the American Medical Association;
Lancet Oncology; Journal of Clinical Oncology; Annals of
Internal Medicine; PLOS Medicine; Circulation; The BMJ;
Journal of the National Cancer Institute) and the journal
Trials between January 2011 and August 2013 (restricted
to studies conducted in adults and published in
English). Additionally, experts were contacted to identify
studies that had not been published at the time of the
search. The review aimed to identify different types of
pilot work undertaken and how they might inform the
design and progression to a main trial. Search terms
included: Adaptive seamless; Adaptive trial; Early phase;
External pilot; Development phase; Feasibility phase;
Feasibility project; Feasibility study; Feasibility trial;
In-built pilot; Internal pilot; Lead in study; Phase II trial;
Pilot study; Pilot trial; Pilot phase; Pilot project; Pilot
work; Pre-testing; Proof of concept; Proof of principle;
Run in phase; Sample size re-estimation design;
Vanguard trial. Publications reporting on full RCTs
without pilot work, reviews, guidance documents and
purely methodological studies were excluded. This
review was considered structured rather than systematic,
as it was not intended to summarise all available evi-
dence on the subject but rather to collate a broadly rep-
resentative set of papers reporting on pilot work to
identify key issues to consider in the next phase of the
study (described below).
After duplications were removed and experts were
contacted for further details where necessary, a total of
309 publications were reviewed and 11 RCTs with an
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internal pilot phase were identiﬁed (table 1). Key ﬁnd-
ings were drawn from this review, which showed that it
was difﬁcult to identify trials with an internal pilot,
perhaps due to poor reporting, lack of prioritisation by
journals as a means to manage demand or because such
trials were relatively uncommon until recently.
Furthermore, reporting of the development and use of
progression criteria in the identiﬁed internal pilot trials
was often missing or lacking detail. These ﬁndings
informed key discussion points at the workshop, includ-
ing deﬁnitions identiﬁed in the ﬁrst review, purpose and
examples of RCTs with an internal pilot phase and
points to consider in developing progression criteria
from an internal pilot to a main trial. Discussions were
minuted and summarised in a report for discussion
within the study group (KNLA, JMB, EOF, PRW, CG). A
detailed summary document was then circulated to all
workshop attendees for comment and feedback.
This paper summarises the main challenges when
developing progression criteria for a trial with an
internal pilot phase, illustrated with examples from a
number of National Institute for Health Research
(NIHR)-funded studies, to inform the optimal design of
efﬁcient RCTs.
Predominant types of progression criteria in an RCT with
an internal pilot phase
A variety of operational progression criteria may be used
to assess the likely success of a trial with an internal
pilot. However, three common issues predominate: trial
recruitment, protocol adherence and outcome data
(table 1). The ﬁrst section of this paper considers each
of these in turn, and approaches to the development
and review of progression criteria, considering also the
role of the Trial Steering Committee (TSC). Next, there
are sections regarding opportunities for using changing
evidence and incorporating this at the juncture of an
internal pilot and main trial. This will allow the formal
determination of optimal design and progression cri-
teria for RCTs with an internal pilot phase. The report-
ing of internal pilot studies is also considered. Finally, 10
top tips for using progression criteria for internal pilot
studies are presented.
Progression criteria
Trial recruitment
Recruitment is most often the focus of progression
criteria14–16 20–29 and a concern for triallists and
funders.30 In the internal pilot phase, investigators may,
for example, estimate the expected prevalence or rate of
incident cases in the population, the number expected
to be screened for eligibility,16 25 the number screened
who are expected to be eligible16 25 or the number eli-
gible who are expected to consent to randomisa-
tion14 15 25 and have prespeciﬁed progression criteria
related to these estimates. A common error when setting
recruitment targets is to deﬁne a target number to be
randomised by a speciﬁed time point. Trials frequently
suffer from delays in the contracting and setting-up of
sites that results in departure from the initial recruit-
ment time plan. It may be more desirable to suggest a
recruitment rate per centre per month.31 The recruit-
ment rate for the pilot phase may thus be informed by
the trial’s recruitment trajectory for achieving the ﬁnal
sample size but recruitment to the substantive phase of
the study may be remodelled later as part of the analysis
of the internal pilot data.
The NIHR By-Band-Sleeve study is an example of a
trial with an internal pilot phase that successfully pro-
gressed to a main trial.18 It was designed to compare the
effectiveness and cost-effectiveness of Roux-en-Y gastric
bypass, adjustable gastric band surgery and sleeve gas-
trectomy for severe and complex obesity. Preagreed
recruitment-related progression criteria speciﬁed that:
(1) 60% of patients referred for bariatric surgery would
meet the eligibility criteria,18 and (2) initially, 30% of
patients would consent to randomisation rising to 50%
after 18 months as recruiters gained in experience and
training with integration of a qualitative recruitment
intervention. The internal pilot found that more
patients than expected (74%) were eligible but that
fewer than expected were randomised. The internal
pilot data were used to inform the main trial design
and, after recruitment rates were adjusted (calculated as
60% eligible, 20% of eligible patients recruited in the
ﬁrst 18 months, 45% thereafter for new centres), the
main trial was given the green light to proceed.25
Further details of the progression criteria outlined in
the By-Band-Sleeve study (and all examples of RCTs with
an internal pilot discussed in this paper) are given in
table 1.
Setting targets for recruitment-based progression cri-
teria can be difﬁcult and practice varies. Targets may be
informed by pre-existing observational data on the
number of incident cases expected during a deﬁned
period of time (eg, from national audit data or data col-
lected by each centre) or on estimates from practising
clinicians. An example is the NIHR-funded TARVA trial,
which was designed to compare the clinical and cost-
effectiveness of total ankle replacement versus ankle
arthrodesis in patients with osteoarthritis.23 The progres-
sion criteria were informed by locally available data from
centres on the number of eligible patients presenting
annually. This was used to inform the minimum recruit-
ment thresholds required to be achieved during the
main trial.
A key decision relating to recruitment-based progres-
sion criteria is the proposed length of the internal pilot
and duration of the recruitment period, the latter of
which has been observed to range from 5 months24 to
over 2 years.16 Often, however, the total period of the
pilot phase is not reported. The duration may be inﬂu-
enced by the volume of patients and the nature (eg,
adherence, variability of outcomes, combined event
rates) of critical information needed. The time taken to
open centres may also impact on timescales, and is
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Table 1 Examples of the variety of progression criteria described in RCTs with an internal pilot phase
Progression criteria
Name of RCT, year Trial objective Recruitment Protocol adherence Outcome data Other
KORAL,14 2010 Multicentre RCT to evaluate the
effectiveness and cost-effectiveness of
arthroscopic lavage for osteoarthritis of the
knee
▸ Proportion of eligible patients
randomised, reasons for refusals
Not applicable/not specified Not applicable/not
specified
Not applicable/
not specified
SUN(^_^)D,15 2012 Multicentre RCT to evaluate the strategic
use of new generation antidepressants for
depression
▸ Demographic and clinical
characteristics of screened and
enrolled patients
▸ Randomisation success
▸ Whether interventions as stipulated in
the protocol are adhered to
▸ Whether blinding had been
successfully implemented
▸ Whether
assessments are
made with
satisfactory
follow-up rates
▸ Inter-rater and
intra-rater
reliability of
primary
outcomes
▸ Safety aspects
EUROTHERM-3235,16
2013
Multicentre RCT to evaluate therapeutic
hypothermia for traumatic brain injury
▸ Feasibility of recruitment (sites
and patients)
▸ Patient eligibility—previous
observational studies had
predicted that 50% of patients
would be eligible
▸ Feasibility of the protocol, in particular
the effectiveness of delivery of the
cooling protocol
Not applicable/not
specified
Not applicable/
not specified
TasP,17 2013 Cluster-randomised community-based RCT
to evaluate the impact of immediate vs
WHO recommendations-guided antiretroviral
therapy initiation on HIV incidence
▸ Evidence that adequate statistical
power for the trial will be achieved
based on a number of
parameters, including: baseline
HIV prevalence; HIV incidence
▸ Evidence that adequate statistical
power will be achieved based on
various parameters, including: initial
and repeated HIV testing uptake;
antiretroviral therapy uptake;
proportion of participants who know
their HIV status and who disclose
their HIV status; migration between
and out of clusters
Not applicable/not
specified
▸ Evidence that adequate
statistical power for the trial will
be achieved based on a
number of parameters, including
extent of sexual partnerships
with people outside trial setting
Progression criteria
Name of RCT, year Trial objective Recruitment Protocol adherence
Completeness and quality
of outcome data Other
By-Band-Sleeve,18
2014
Multicentre RCT to compare the effectiveness
and cost-effectiveness of Roux-en-Y gastric
bypass and adjustable gastric band surgery to
treat severe and complex obesity
▸ 60% of patients referred for
bariatric surgery to be
eligible for the trial (if
necessary, revising the
eligibility criteria)
▸ Initially, 30% and then 50%
of patients consent to
randomisation
▸ <5% failure to receive
allocated intervention
▸ <15% lost to follow-up Not applicable/
not specified
COMMANDO,19 2014 Multicentre RCT to treat childhood obesity in the
community using Mandolean therapy (a portable
food weighing scale that provides feedback to
participants to promote normal patterns of eating
and satiety)
▸ Recruitment of ≥36 families
who would be eligible for
the main study
▸ 90% of patients randomised
to Mandolean therapy would
be successfully eating off
the device at least five times
a week
▸ ≥80% would attend the
3-month nurse
appointment for both
study groups
▸ ≥60% of those using Mandolean
therapy would demonstrate a
decrease in speed of meal
consumption (longer meals) since
baseline within 3 months of
starting therapy
Continued
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Table 1 Continued
Progression criteria
Name of RCT, year Trial objective Recruitment Protocol adherence
Completeness and quality
of outcome data Other
NERVES,20 2014 Multicentre RCT to evaluate the effectiveness
and cost-effectiveness of transforaminal epidural
steroid injection to surgical microdisectomy for
acute sciatica
▸ Recruitment of ≥30 patients
in 6 months
▸ Consent rate of ≥40%
▸ ≤20% failure to receive the
alternative intervention
▸ <50% of patients in
injection group proceed to
surgery
Not applicable/
not specified
PLINY,21 2014 Multicentre RCT to evaluate the effectiveness
and cost-effectiveness of telephone befriending
to maintain quality of life in older people
▸ Recruitment of ≥68
participants in 95 days
▸ Service provider (a national
charity) should recruit, train
and retain enough
volunteers to deliver the
telephone befriending
service
▸ Collect valid primary
outcome data for 56
(80%) of those recruited at
the 6 month follow-up
Not applicable/
not specified
Sheffield physical
activity ‘Booster’,22
2014
Single-centre community-based RCT to evaluate
the effectiveness and cost-effectiveness of
‘booster’ interventions to sustain increased
physical activity in middle-aged adults in 55
deprived urban neighbourhoods
▸ 60 participants recruited ▸ ≥70% of those randomised
to Booster interventions
receive interventions per
protocol
▸ ≥75% of those recruited
to provide 3 months
follow-up measures,
including primary outcome
measure
Not applicable/
not specified
TARVA,23 2014 Multi-centre RCT to compare the clinical and
cost-effectiveness of total ankle replacement vs
ankle arthrodesis
▸ 33 patients (10% of total
target recruitment
randomised in 6 months)
▸ 82 patients (25% of total
sample size) recruited in
15 months
▸ Patient willingness to be
randomised
▸ Surgeon willingness to
randomise
▸ Whether requiring surgical
competence in both
procedures limits
recruitment
Not applicable/
not specified
Not applicable/
not specified
Not applicable/
not specified
VIOLET,24 2015 Multicentre RCT to compare video-assisted
thoracoscopic lobectomy vs conventional open
lobectomy for lung cancer
▸ 20 eligible patients
screened per month
▸ 30% of eligible patients
recruited initially, increasing
to 50% within 6 months at
each centre
Not applicable/
not specified
Not applicable/
not specified
Not applicable/
not specified
‘Not applicable/not specified’: no formal progression criteria proposed or detailed in trial report(s).
RCT, randomised controlled trial.
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inﬂuenced by the experience of the participating
centres, ensuring that contracts are in place and the
teams are able to deliver the interventions. A progres-
sion criterion may therefore include the number of
centres that are expected to open within a speciﬁed
period. A pilot phase needs to be sufﬁciently long to
accommodate delays with opening centres and allow var-
iations in patient ﬂow to be documented over time to
provide a fuller picture of the activity spread across a
number of centres that would mimic the main trial.
Consideration of whether recruitment rates have sea-
sonal ﬂuctuations is also recommended.
The issues discussed above are inﬂuenced by the
number and type of centres that are expected to open
and begin recruitment in the pilot within a deﬁned
period.24 Pilot centres may be chosen because this is
where the co-applicants work, are close in proximity or
they are where natural collaborations already in place.17
Selecting ‘home’ or otherwise safe and ‘enthusiastic’
centres brings potential beneﬁts, including keeping
more of the grant funding in house, thus ironing out
difﬁcult issues (eg, with contracts) with familiar staff
before rolling out to other centres, and being able to
visit centres promptly should issues arise. This may,
however, lead to overestimation of recruitment that
might not be replicated across centres participating in
the main trial. Aiming for centres with a mixture of pre-
vious experience of recruitment success, enthusiasm or
resources is recommended to reﬂect the reality of data
collection. The ongoing NIHR-funded VIOLET study,
which is comparing video-assisted thoracoscopic lobec-
tomy and conventional open lobectomy for lung
cancer,24 is an example of a surgical trial with an
internal pilot in which the ﬁve pilot centres have been
deliberately selected to include a range of research
experience, to gain a realistic picture of feasibility.
Protocol non-adherence
A second set of progression criteria focus on the assess-
ment of protocol non-adherence. Assessment may
include all protocol procedures,32 although most often
the focus is on adherence to the intervention. There are
two main types of non-adherence: ‘cross-over’ and ‘off-
protocol intervention’.1 Cross-over refers to a participant
not receiving their allocated intervention and instead
receiving an alternative trial intervention to which they
were not allocated. Cross-over has the potential to
reduce the power of the study because study groups may
become more similar and the difference between over-
lapping groups is smaller than expected.33 34 This may
be overcome by inﬂating the sample size to account for
a certain rate of cross-over,34 35 so a progression criterion
may relate to whether cross-over is within the rate
allowed for in the sample size inﬂation. Off-protocol
intervention describes the situation when another inter-
vention (whether experimental or standard, a switch to
another ﬁrst-line intervention due to side effects from
their allocated intervention or a second-line intervention
due to disease progression) not included in the inter-
vention protocol is used. Switches to off-protocol inter-
ventions may make the randomised groups more similar
or more different in outcome.36 Non-adherence to the
interventions may arise when patients or clinicians
decline or cease the allocated intervention after ran-
domisation and decide to select an intervention other
than that allocated by randomisation (either in another
trial group or an off-protocol intervention). In a trial in
which patients are blinded to their allocation and/or
the interventions on offer, it is less common for cross-
over to occur, although a patient could request an inter-
vention outside the study (off-protocol intervention).
Non-adherence may also arise if there are problems with
the acceptability of the intervention protocol, such as
when side effects or adverse events are experienced.
Experience in the pilot phase may inform the main
trial procedures to enhance adherence. It may also allow
a fuller understanding of potential issues with the feasi-
bility of the protocol and the overall trial design. An
example is the ‘SUN-D’ trial (supported by the
Grant-in-Aid by the Ministry of Health, Labour and
Welfare, Japan), which investigated the optimal ﬁrst-line
and second-line antidepressant interventions for major
depression.15 After the ﬁrst 8 months of the multicentre
pilot phase, investigators found that a proportion of
patients had not reached their intended dosage by the
scheduled time points. Minor changes were made to the
main trial protocol to allow greater ﬂexibility in the dose
titration schedules and the internal pilot has since pro-
gressed to the main trial. The introduction of protocol
modiﬁcations shows that knowledge of problems with
intervention adherence can facilitate a successful main
trial, though a further pilot period may be needed to
show that the progression criteria are being met follow-
ing a modiﬁcation.
While the rate and direction of cross-over are often
well reported in trials, details about off-protocol inter-
vention are less so. This may be due to difﬁculties in
obtaining this information or pragmatic decisions on
what information to publish due to journal word count
restrictions. Furthermore, formal quantiﬁable progres-
sion criteria set around maximum targets for cross-over
or off-protocol intervention speciﬁcally (as opposed to
the broader issue of non-adherence) are relatively
rare.14 18 26 27 In the NIHR-funded KORAL study, a
placebo-controlled trial of arthroscopic lavage for osteo-
arthritis of the knee, rates of cross-over and withdrawal
were monitored and contributed (along with other
issues that emerged during the internal pilot, including
a decline in the use of arthroscopic lavage in clinical
practice) to the main trial being stopped, but formal
quantiﬁable progression criteria set around cross-over
were not detailed.14 Conversely, the ongoing
NIHR-funded NERVES trial, a pragmatic trial with an
internal pilot phase comparing nerve root injection with
surgery for acute sciatica,20 did specify stop/go rules.
They agreed in advance that if more than 50% of
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patients in the injection group cross-over to surgery, the
TSC/Independent Data Monitoring Committee (DMC)
will evaluate the reasons for cross-over and consider stop-
ping the main trial. Recruitment-based progression cri-
teria in NERVES were informed by Hospital Episode
Statistics data for the numbers of surgeries performed
annually in each centre.
Observed cross-over needs to be within that allowed
for in the sample size calculation. However, uncertainty
remains around how protocol adherence may be moni-
tored and when non-adherence should result in modiﬁ-
cations or prevent continuation to the main trial. These
issues need to be considered on a trial-by-trial basis.
Detailing the reasons for cross-over and off-protocol
interventions received during an internal pilot will help
inform the design of the main trial, for example, by
alluding to problems with patient information, the feasi-
bility of the intervention or assessment protocol, site
training and recruitment processes. If non-adherence is
a substantial issue, potentially compromising the statis-
tical power of the main trial, it may be better to not pro-
gress to the main trial and reconsider its design (the
issue of when to opt for other types of pilot studies is
discussed below).
Outcome data
Monitoring the completeness and quality of short-term
outcome data during an internal pilot provides a valu-
able opportunity to identify any problems and initiate
changes to conduct to improve data collection in the
main trial. Ideally, each trial participant will contribute
complete data, collected at predetermined time points,
as outlined in the protocol. In practice, however, missing
or inadequate data are inevitable, meaning that some
participants will not be included in the outcome assess-
ment. The amount of missing data can have important
implications for the trial’s required sample size. The
most common reason for missing or inadequate data is
attrition or loss to follow-up (for reasons such as death,
poor health, loss of interest, moving out of the area) or
problems with the feasibility or acceptability of the
outcome assessment protocol (eg, organisational issues,
amount/timing of assessments) or the outcome
measure instruments themselves (eg, lack of applicabi-
lity, problems with comprehension). Even when some
data are available, its quality may be poor; for example,
items on a patient-reported outcome measure may be
only partly completed or data may not have been col-
lected promptly, resulting in only a small percentage of
patients providing usable assessments within an accept-
able time frame. Assessing rates of completeness of
outcome data to report with the progression criteria can
therefore be useful and may form a focal point for pro-
gression criteria in particular clinical settings.
For example, in the Putting Life in Years (PLINY)
trial, funded by the NIHR, there was a prespeciﬁed
target of collecting valid primary outcome data for 80%
of those recruited at the 6-month follow-up in the
internal pilot phase.21 Another example is the Shefﬁeld
trial of physical activity ‘booster’ interventions to sustain
increased physical activity in middle-aged adults in
deprived urban neighbourhoods. The progression cri-
teria speciﬁed that at least 75% should provide 3-month
follow-up measures, including the primary outcome
measure, to ensure that the trial would be powered to
show an effect if one existed.22 Despite not fulﬁlling this
(and other) progression criteria, the main trial pro-
ceeded with design modiﬁcations (although the trial
eventually closed early due to poor recruitment and
retention of participants with primary outcome acceler-
ometer data). This is potentially an example of an
‘amber’ situation following the internal pilot, where
there may have been some reservations about proceeding
to the main trial. In amber situations, there may be
remediable issues that would otherwise prevent progres-
sion to the main trial but that, if identiﬁed early enough,
can be addressed to the satisfaction of those reviewing
progress in order for the trial to continue to a main trial.
In contrast, the COMMANDO trial,19 funded by the
NIHR, was an example of an RCT that was stopped after
the internal pilot. COMMANDO looked at changing
eating behaviours in obese children, using a portable
computerised weighing scale called a Mandolean that
provided feedback to participants to promote normal pat-
terns of eating and satiety. Progression criteria included
that 36 or more families would be eligible for the main
study, that 90% of patients randomised to Mandolean
therapy would eat off the device at least ﬁve times a week,
that using the Mandolean would reduce the speed of
meal consumption within 3 months and that 80% of par-
ticipants would provide data at their 3-month follow-up
appointment. However, the pilot failed to meet any of its
progression criteria and the trial was stopped.
In many cases, progression criteria set around key
outcome data do not detail speciﬁc targets for complete-
ness or quality14–17 22 26–28 37 38 or focus only on certain
aspects of attrition.15 18 21 22 Assessing the completeness
and quality of outcome data in an internal pilot may not
be appropriate if the primary outcome cannot be
assessed in any or the majority of the patients within the
lifespan of the internal pilot. Assessing shorter term
follow-up may offer some insight into likely retention
rates in the main trial but there is the potential for over-
estimating target retention rates.
Approaches to the development and review of progression
criteria
Current practice in the NIHR Health Technology
Assessment (HTA) programme, which may be similar to
other funding bodies, is for progression criteria to be
preagreed between the trial team and funder at the
application stage. This agreement will include a decision
about the length of the internal pilot and when to
submit data on progression criteria that can be discussed
at a ‘monitoring visit’ such as those carried out by the
NIHR HTA programme. It is important to carefully
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schedule (though with ﬂexibility, if required) discussions
about progression criteria to ensure that they are soon
enough to avoid unnecessary effort and expenditure on
an unfeasible study but that sufﬁcient time has passed to
gain useful information and to allow a reasonable time
window for discussions and modiﬁcation of the main
trial or the progression criteria (or both) if required.
While it is often easier to judge whether an internal
pilot should proceed to a main trial, in practice whether
an internal pilot has failed to achieve its target(s)
requires a more complex judgement. Trials may fall into
the amend zone due to a factor that severely reduces
recruitment but is temporary and remediable (such as a
trial manager having sickness absence) and therefore
does not require stopping the trial. It is unlikely that a
trial would be stopped according to a predetermined
rule without considering whether there are remediable
factors. In contrast, if a trial is clearly failing with no
obvious remediable cause, then a decision to stop the
trial may be reached more quickly.
Information or data relating to progression criteria
should not be considered in isolation. Supplementary
data may serve to facilitate decision-making about
whether the main trial should proceed even when pro-
gression criteria have not been met. Funding bodies have
acknowledged the value of considering not just whether
studies have achieved their progression criteria but all
relevant information on trial progress. Supplementary
data that may be included in an internal pilot report
may encompass how the trial team has responded to and
overcome problems that have arisen (eg, overcoming
unexpected excess intervention costs or barriers to
recruitment). Funders may offer the opportunity to
submit a ‘rescue plan’ that outlines how problems may
be overcome for the main trial, with revised progression
criteria.39 The protocol for the NIHR HTA-funded
TARVA (total ankle replacement vs ankle arthrodesis for
osteoarthritis) trial, for example, speciﬁes that failure to
meet the recruitment target set in the feasibility phase
(ie, 10% of the recruitment target has not been reached
6 months into recruitment) will trigger submission of a
plan to the funder, based on an options appraisal under-
taken by the Trial Management Group and outlining the
actions to be taken to improve recruitment to ensure that
the target is met.23 Consideration would then be given to
halting the trial had targets still not been met 15 months
into recruitment. Alternatively, meeting all prespeciﬁed
progression criteria at the end of the internal pilot phase
does not automatically guarantee continuation to and
throughout the main trial, as important factors (eg, pro-
gress with recruitment) will typically continue to be mon-
itored throughout the entirety of the trial.
The key role of the TSC
It may be argued that consideration of trial progression
is not new and that this is routinely considered by a
TSC. The TSC provides independent oversight of a trial
on behalf of the sponsor and funder and considers and
acts on the recommendations of the DMC, or equiva-
lent. Rather than review progression criteria, however,
the DMC considers information collated about the
ongoing trial, including statistical criteria (often called
stopping rules), and may recommend whether to stop
the trial, typically on grounds of safety or efﬁcacy, and
sometimes futility,40–42 though often stopping rules do
not consider futility or deliverability of the trial at such
an early stage as the review of progression criteria in an
internal pilot. The decisions and recommendations
made by a TSC across a trial’s lifespan may be consid-
ered to overlap somewhat with the formal review of pro-
gression criteria undertaken between the TSC, trial
team and funder at the end of the internal pilot phase,
yet there are important differences. The main difference
is that the trial team has preagreed that if progression
criteria are not being met, then the trial may be
stopped. The added value of a trial with an internal
pilot phase is, therefore, focus on achieving the criteria
and, where problems arise, ﬁnding solutions earlier
than if the trial was being conducted without an internal
pilot. The TSC typically plays an integral role in how
information about progression criteria is fed back to the
funder, particularly if the trial is in the amber zone
where progression to the main trial is uncertain. If this
happens, ongoing communication between the trial
team, the TSC and the funder may be necessary until it
is agreed that amber issues have been resolved and it is
considered appropriate that the main trial continues.
Using changing evidence during the internal pilot phase
of an RCT
The design of an RCT with an internal pilot phase will
be based on current best evidence available during the
planning stages. However, critically important new infor-
mation may become available during the course of a
trial that may be considered sufﬁcient to require
changes to its trial design. The use of an internal pilot
design may serve as an added opportunity to make oper-
ational modiﬁcations to the main trial, for example,
inclusion of a new intervention established during the
internal pilot phase of a trial, where there is knowledge
of the innovation of a new surgical technique. This is dif-
ferent from an adaptive trial design, which allows modiﬁ-
cations to the design of the trial, its statistical procedures
or its hypotheses that are typically planned in advance
and possibly substantive.42
At the time the original By-Band study was being
designed,18 interest in a novel type of bariatric surgery—
laparoscopic sleeve gastrectomy—was growing. In
response to this, progression criteria agreed in the
internal pilot phase included a review of current prac-
tice of sleeve gastrectomy by the end of the pilot phase,
to understand whether uptake and standardisation of
the procedure was sufﬁcient to extend the main trial to
include a third intervention group and review of new
evidence that may have accumulated in this area. The
review showed a signiﬁcant increase in the number of
8 Avery KNL, et al. BMJ Open 2017;7:e013537. doi:10.1136/bmjopen-2016-013537
Open Access
group.bmj.com on September 29, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
sleeve gastrectomy procedures being undertaken in the
UK and, after the internal pilot phase, By-Band was
adapted to a three group trial, By-Band-Sleeve.
Reporting of internal pilot trials
The ﬁndings from pilot work, including RCTs with an
internal pilot phase, are often reported as inconclusive
and difﬁcult to interpret.10 In addition, the assumption
that pilot studies are less rigorous than main studies and
are not designed to test the main trial hypothesis means
that their ﬁndings are underdisseminated, thereby pre-
venting triallists from accessing information that may be
valuable to the success of future main trials.3 10 The sys-
tematic reporting and publication of the design, results
and evaluation of internal pilot trials in the literature
should be encouraged to enable triallists to gain experi-
ence in interpreting the results of internal pilots and to
learn from the experiences of internal pilots that have
not progressed to a main trial (eg, where an RCT with
an internal pilot is stopped early). These ‘failed’ trials
may provide valuable insights into the types of chal-
lenges that triallists face when designing and conducting
internal pilot trials that may inform future trials, in add-
ition to saving resources on a main trial that is unlikely
to succeed.9 14 43 ‘Pilot and feasibility studies’ is a new
open access journal that is committed to ensuring that
the results of all well-conducted, peer-reviewed, pilot
and feasibility studies are published, regardless of the
outcome or signiﬁcance of the ﬁndings.44 Where an
internal pilot has progressed to a main trial, the subse-
quent report of the main trial should clearly describe
the internal pilot phase, so that its impact on the design
of the main trial can be understood. Greater transpar-
ency in reporting how decisions were made to proceed
with, amend or abandon the main trial, particularly in
relation to the progression criteria, is also required.
Recently, a new reporting guideline for external pilot
and feasibility studies has been published as an exten-
sion to the CONSORT statement.45 46 Similar guidelines
for internal pilot studies may be useful to facilitate
understanding of their purpose, enable journals to
better evaluate the rigour of such studies and aid their
interpretation in the literature.
Details provided in study protocols of the internal
pilot phase of an RCT and any associated progression
criteria also vary widely. Often, detail included in a
funding application may not be included in the protocol
or subsequent reports. It is also possible that progression
criteria are only agreed with the funder after funding
has been granted and the protocol developed, and so
not included in the protocol. This raises issues about the
level of detail that should be required in study protocols.
Ten top tips for developing and using progression criteria
for internal pilot studies
Ten top tips for developing and using progression cri-
teria for internal pilot studies are proposed (box 1).
These tips include suggestions for specifying and
assessing progression criteria and the detailed reporting
of internal pilot studies.
DISCUSSION
An internal pilot phase within an RCT allows key aspects
of trial conduct to be established in a subset of centres
before expansion into the main trial. The preagreement
of stop/amend/go progression criteria to be reported to
the funder provides a focus to optimise pilot work and
the subsequent main trial. A formal internal pilot trial
design also allows a trial to be abandoned if key criteria
demonstrate that a main trial is not realistic to under-
take even with some modiﬁcations in design.
Progression criteria predominantly focus on trial recruit-
ment, although protocol adherence and follow-up cri-
teria are often assessed and reported. This paper has
summarised the key issues to consider in the develop-
ment of operational progression criteria for internal
pilot studies, in order to inform efﬁcient RCT design.
Previously, guidance in this area has been lacking,
accompanied by uncertainty about how progression
Box 1 Ten top tips for developing and using progression
criteria for internal pilot studies
1. A traffic light system of green (go), amber (amend) and red
(stop) might be preferable to a simple stop/go approach when
specifying progression criteria for internal pilot studies;
2. Pre-specified progression criteria agreed with funders need to
strike a careful balance between being firm enough to promote
ambition in the trial team yet being flexible enough to allow
opportunities to remedy early problems;
3. Recruitment progression criteria should be based on rates per
centre per unit time (eg, per month) that can be easily extrapo-
lated, rather than specifying that an absolute number should be
reached by a specific date, due to the unpredictability of opening
sites;
4. When recruitment falls behind, it is essential to explore screen-
ing logs to determine whether insufficient participants were
approached, insufficient participants passed eligibility criteria or
insufficient eligible participants agreed to randomisation;
5. The assessment of intervention adherence, cross-over and
outcome event rates should take into account the duration from
randomisation to timing of primary outcomes if sufficient data are
to be gleaned in time to inform progression;
6. When assessing missing data, it is important to explore the
degree of missing data within key outcomes as well as the per-
centage of participants with missing data;
7. Trial teams should involve both their funders and their Trial
Steering Committee in assessing their progression criteria;
8. Pilot study recruitment sites should be representative of sites
that recruit into the main study;
9. Triallists may be able to take the opportunity to assess whether
changes to existing technologies have occurred since the original
study was planned, so that new technologies can be considered
with funders, such as using an adaptive design;
10. Pilot studies need to be reported fully. An extension to
CONSORT guidelines for pilot and feasibility studies is now
available.
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criteria should be applied and reviewed. Top tips for
developing and using progression criteria for internal
pilot studies are proposed.
When to use an internal pilot
Designing an RCT with an internal pilot phase is
unlikely to be appropriate in most situations where sub-
stantive changes to key components of the trial, such as
the intervention or outcomes, are likely to be required
but is appropriate where there is some uncertainty
around key areas that could inﬂuence the success of the
trial, such as recruitment. They may also be recom-
mended where participating centres and chief investiga-
tors have limited experience with trials. While data
collected during an internal pilot may inform decisions
to make minor modiﬁcations to the design and conduct
of the main trial phase (eg, to sampling and/or recruit-
ment or the intervention protocol), such modiﬁcations
should not be expected to reduce the ability of the pilot
data to contribute to the main study.
An internal pilot may also be considered where teams
have limited experience of conducting multicentre
trials. The pilot phase then also acts as an opportunity
to test whether successful collaborations can be devel-
oped and trial processes run across multiple centres.
This has been exempliﬁed recently with surgical teams
in the UK beginning to collaborate, design and conduct
RCTs when previously it was uncommon. Over the past
decade, there has been a steady increase in the number
of NIHR multicentre trials funded and many are
designed with an internal pilot phase.
Unexpected problems resulting in substantive changes
to recruitment, protocol adherence, outcome data or
other aspects of design, particularly the intervention
and the outcomes, may prevent inclusion of data from
the internal pilot in the main trial analyses. It is there-
fore important to know in advance of the internal pilot
phase which outcomes will be measured in the main
trial and how, so that relevant data are collected
throughout. When there is considerable uncertainty or
risk around the design of the main trial, or when sub-
stantive changes are anticipated, other types of pilot
work that allow for more substantial design amend-
ments, such as an external pilot trial, are likely to be
more appropriate. For example, where uncertainties
about the availability of eligible patients or the ability to
recruit prevent producing reliable recruitment targets,
the NIHR HTA recommends that researchers consider
applying for an external rather than an internal pilot.39
However, there is a place for more pragmatic trials,
which allow greater variation in trial procedures in
order to maximise generalisability and provide evidence
relevant to clinical practice and policy if transparently
designed and reported.47 Recent work to develop a
checklist for systematically documenting design modiﬁ-
cations during pilot trials may help to inform decisions
about whether it is advisable to pool data from the pilot
phase and the main trial.47 Further work to categorise
the magnitude of design modiﬁcations to an RCT with
an internal pilot phase and to develop recommenda-
tions to facilitate decision-making about pooling data is
ongoing.47 Work to further reﬁne deﬁnitions of different
types of pilot and feasibility studies is needed to support
decision-making regarding the design of pilot work for
RCTs.
While developed with RCTs with an internal pilot
phase in mind, it is possible that the recommendations
for progression criteria presented in this paper may also
be applicable to decisions regarding the main trial
conduct and design following an external pilot study.
Practicality of RCTs with an internal pilot phase
When designing a trial with an internal pilot phase, trial-
lists should take care to ensure that the use of progres-
sion criteria, which will often quantify targets (eg, for
the recruitment of patients or opening of centres), does
not counteract progress. Often, an internal pilot phase
will be conducted in a subset of all centres to be opened
within the main trial phase, and a progression criterion
may include the number of centres to be opened within
a given period. If, however, it is possible to open add-
itional centres during that time, then it may be detri-
mental to the trial not to do this. Consideration should
also be given to ensure that the time taken to prepare
the report from the internal pilot phase and for the trial
team, TSC and funder to review progress against pro-
gression criteria does not inhibit seamless transition to
the main phase of the trial.
Better reporting of internal pilot RCTs is needed
Currently, detailed reporting of progression criteria, and
how funders review and act on information about pro-
gress against these criteria, is uncommon and it is difﬁ-
cult for triallists to learn from past experience. It is
recommended that progression criteria are reported
clearly in a trial protocol paper and subsequent protocol
update papers and trial reports, alongside how trial
teams met/did not meet criteria and how the funding
body responded to this information, to inform the
future development, presentation and optimisation of
criteria in trial design.
CONCLUSIONS
Designing studies with an internal pilot phase may opti-
mise the use of pilot work to inform more efﬁcient RCTs.
The careful selection of preagreed progression criteria
provides a valuable opportunity to formally review
complex trial processes, inform decisions about trial
conduct and whether continuation to the main trial is
appropriate. This has the potential for the trial team and
funder to identify and address problems that may jeop-
ardise the success of the main trial sooner than would
have been possible without an internal pilot phase. It has
the added potential to avoid waste of valuable resources.
This paper outlines common issues to consider in the
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optimal development and review of operational progres-
sion criteria. Describing the internal pilot phase of an
RCT in trial protocols is recommended, and detailed
and systematic reporting of internal pilot studies is
encouraged to aid triallists in their design, and to facili-
tate their evaluation by journals and their interpretation
in the literature. Transparent reporting around the
choice of trial design and the decision-making process
for stopping, amending or proceeding to a main trial
should be regarded by the research community as bene-
ﬁcial to facilitating understanding of the appropriate and
optimal use of RCTs with an internal pilot phase.
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